AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7657105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (5 mg.kg‐1.day‐1)
Number of subjects: 182
Study 7657105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 7657105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 182
Study 2765229 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser excision
Number of subjects: 18
Study 2765229 — intervention group
Group type: COMPARATOR
Intervention: Scalpel excision
Number of subjects: 18
Study 4923930 — intervention group
Group type: EXPERIMENTAL
Intervention: Medazepam 10 mg three times a day
Number of subjects: 0
Study 4923930 — intervention group
Group type: COMPARATOR
Intervention: Amylobarbitone 60 mg three times a day
Number of subjects: 0
Study 31978238 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review (LR) therapy provided by family caregivers
Number of subjects: 19
Study 31539430 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Fresh Whole Blood (FWB) transfusion training
Number of subjects: 3408
Study 27838475 — intervention group
Group type: COMPARATOR
Intervention: In-person intervention (n=30)
Number of subjects: 160
Study 27838475 — intervention group
Group type: COMPARATOR
Intervention: Online intervention (n=50)
Number of subjects: 160
Study 27838475 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n=30)
Number of subjects: 160
Study 27838475 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n=50)
Number of subjects: 160
Study 25921522 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-directed patient self-management therapeutic strategy based on left atrial pressure (LAP) measured twice daily by an implantable sensor
Number of subjects: 730
Study 25921522 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 730
Study 23563072 — intervention group
Group type: EXPERIMENTAL
Intervention: Logotherapy (My Precious Life program, one session per week for five weeks)
Number of subjects: 142
Study 23563072 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=72)
Number of subjects: 142
Study 22089242 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping (≥ 180 seconds after delivery)
Number of subjects: 400
Study 22089242 — intervention group
Group type: COMPARATOR
Intervention: Early clamping (≤ 10 seconds after delivery)
Number of subjects: 400
Study 19786657 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with leucovorin and fluorouracil after six cycles of mFOLFOX7 (arm 1)
Number of subjects: 202
Study 19786657 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy-free interval (CFI) after six cycles of mFOLFOX7 (arm 2)
Number of subjects: 202
Study 17482432 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (50-400 mg/day)
Number of subjects: 72
Study 17482432 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (0.5-2 mg/day)
Number of subjects: 72
Study 15015164 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐Y advancement
Number of subjects: 35
Study 15015164 — intervention group
Group type: COMPARATOR
Intervention: Simple continuous suturing
Number of subjects: 35
Study 11695749 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant orthopaedics (IO+) - passive maxillary plates during the first year of life
Number of subjects: 2
Study 11695749 — intervention group
Group type: COMPARATOR
Intervention: Control group (IO-) - no passive maxillary plates
Number of subjects: 2
Study 11695749 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant orthopaedics (IO+)
Number of subjects: 2
Study 9142026 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (inspiratory and expiratory positive airway pressures of 15 and 5 cm H2O, respectively)
Number of subjects: 27
Study 9142026 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP at 10 cm H2O)
Number of subjects: 27
Study 9142026 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure
Number of subjects: 27
Study 9142026 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure and CPAP
Number of subjects: 27
Study 7965482 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-based ORS solution
Number of subjects: 97
Study 7965482 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose-based ORS solution
Number of subjects: 97
Study 3655273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g q.i.d. for 8 weeks
Number of subjects: 42
Study 3655273 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg q.i.d. for 8 weeks
Number of subjects: 42
Study 29154608 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional awareness and expression interview
Number of subjects: 75
Study 26311735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy-based techniques targeting grief, loss, and change
Number of subjects: 61
Study 26311735 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 61
Study 24589500 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75% (IQ3.75%)
Number of subjects: 0
Study 24589500 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 23252525 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg if weight ≥30 kg or 12 mg/kg if weight <30 kg) given intravenously every 2 weeks for 12 weeks
Number of subjects: 112
Study 23252525 — intervention group
Group type: COMPARATOR
Intervention: Placebo given intravenously every 2 weeks for 12 weeks
Number of subjects: 112
Study 20517827 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (50 mg/kg bolus followed by 10 mg/kg/h for 24 hours)
Number of subjects: 42
Study 20517827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline solution)
Number of subjects: 42
Study 17991790 — intervention group
Group type: EXPERIMENTAL
Intervention: Added external dead space (DS) of 200, 400, and 600 ml
Number of subjects: 12
Study 17991790 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no added dead space)
Number of subjects: 12
Study 16268802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 60 mg
Number of subjects: 18
Study 16268802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 90 mg
Number of subjects: 18
Study 16268802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg
Number of subjects: 18
Study 16268802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (all doses)
Number of subjects: 18
Study 12132061 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 35 microg with saline (F)
Number of subjects: 80
Study 12132061 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2.5 mg + saline (FB)
Number of subjects: 80
Study 12132061 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2.5 mg + epinephrine 100 microg (FBE)
Number of subjects: 80
Study 12132061 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 100 microg + saline (FE)
Number of subjects: 80
Study 10072142 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 56697 (4 x 4 tablets each containing 20 mg of artemether and 120 mg of benflumetol, given at 0, 8, 24, and 48 hr)
Number of subjects: 252
Study 10072142 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine (three tablets of 250 mg at initial diagnosis, followed by two tablets of 250 mg at 8 hr)
Number of subjects: 252
Study 10072142 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 56697
Number of subjects: 252
Study 10072142 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 252
Study 7487854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (modification of negative cognitions)
Number of subjects: 52
Study 7487854 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of information (about oral health and dental treatment)
Number of subjects: 52
Study 7487854 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 52
Study 1828134 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 74
Study 1828134 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin
Number of subjects: 74
Study 6971244 — intervention group
Group type: EXPERIMENTAL
Intervention: Azidocillin
Number of subjects: 84
Study 6971244 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 84
Study 29309387 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Pressure Ventilation (PPV)
Number of subjects: 9
Study 29309387 — intervention group
Group type: COMPARATOR
Intervention: NO‐PPV
Number of subjects: 9
Study 29309387 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV and NO‐PPV
Number of subjects: 9
Study 31746528 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-0379 (0.1%) sprayed on skin ulcers once per day for 4 weeks
Number of subjects: 8
Study 31746528 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-0379 (0.1%)
Number of subjects: 8
Study 28958431 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding a load corresponding to 5% body mass in the left hand
Number of subjects: 65
Study 28958431 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding a load corresponding to 5% body mass in the right hand
Number of subjects: 65
Study 28958431 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding a load corresponding to 5% body mass in both hands
Number of subjects: 65
Study 28958431 — intervention group
Group type: COMPARATOR
Intervention: Standing without holding a load
Number of subjects: 65
Study 26934969 — intervention group
Group type: EXPERIMENTAL
Intervention: MOUTh intervention (Managing Oral Hygiene Using Threat Reduction Strategies)
Number of subjects: 0
Study 24201414 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 ml/h infusion of 30 mg nefopam
Number of subjects: 102
Study 24201414 — intervention group
Group type: COMPARATOR
Intervention: 120 ml/h infusion of 30 mg nefopam
Number of subjects: 102
Study 24201414 — intervention group
Group type: COMPARATOR
Intervention: 180 ml/h infusion of 30 mg nefopam
Number of subjects: 102
Study 23050401 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis (n=50)
Number of subjects: 75
Study 23050401 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-periodontal subjects (n=25)
Number of subjects: 75
Study 20031844 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic intervention delivering key evidence-based reminders to home care nurses and patients
Number of subjects: 845
Study 20031844 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented intervention including basic intervention plus ongoing Hypertension Home Support Program for 12 months
Number of subjects: 845
Study 20031844 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 845
Study 17805582 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 500 mg PO every 6 h
Number of subjects: 34
Study 17805582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16607045 — intervention group
Group type: COMPARATOR
Intervention: Basal treatment (aspirin 162 mg + cilostazol 200 mg/day)
Number of subjects: 165
Study 16607045 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI (basal treatment + quinapril 10 mg or perindopril 4 mg/day)
Number of subjects: 165
Study 16607045 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB (basal treatment + losartan 50 mg/day)
Number of subjects: 165
Study 12943062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 129
Study 12943062 — intervention group
Group type: COMPARATOR
Intervention: Broad-spectrum beta-lactam antibiotics (Control)
Number of subjects: 129
Study 11004423 — intervention group
Group type: EXPERIMENTAL
Intervention: Language inclusive meta-analyses
Number of subjects: 79
Study 11004423 — intervention group
Group type: COMPARATOR
Intervention: Language restricted meta-analyses
Number of subjects: 79
Study 8851092 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic technique (n = 150)
Number of subjects: 285
Study 8851092 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser technique (n = 100)
Number of subjects: 285
Study 8851092 — intervention group
Group type: COMPARATOR
Intervention: Non-laser technique
Number of subjects: 285
Study 8851092 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fimbrial eversion with laser (n = 10)
Number of subjects: 285
Study 8851092 — intervention group
Group type: COMPARATOR
Intervention: Suture eversion (n = 10)
Number of subjects: 285
Study 1507816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordarone (intravenous)
Number of subjects: 81
Study 1507816 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (intravenous)
Number of subjects: 81
Study 1507816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajmaline (intravenous)
Number of subjects: 81
Study 1507816 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (intravenous)
Number of subjects: 81
Study 1507816 — intervention group
Group type: EXPERIMENTAL
Intervention: Novocaine amide (intravenous)
Number of subjects: 81
Study 1507816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacizin (intravenous)
Number of subjects: 81
Study 1507816 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (oral)
Number of subjects: 81
Study 1507816 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinilentin (oral)
Number of subjects: 81
Study 1507816 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (oral)
Number of subjects: 81
Study 1507816 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (oral)
Number of subjects: 81
Study 1507816 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexitil (oral)
Number of subjects: 81
Study 1507816 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall efficacy of antiarrhythmic therapy
Number of subjects: 81
Study 6343416 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg/h)
Number of subjects: 5
Study 6343416 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (6.5 ml/h)
Number of subjects: 5
Study 30457058 — intervention group
Group type: EXPERIMENTAL
Intervention: Germination test
Number of subjects: 4
Study 30457058 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Conductivity test
Number of subjects: 4
Study 30457058 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth analysis
Number of subjects: 4
Study 29761751 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (integrated physical and mental healthcare)
Number of subjects: 387
Study 29761751 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 387
Study 26822311 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIMA-eDS tool
Number of subjects: 3500
Study 26822311 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 3500
Study 24569914 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-100 at 0.2 µg (Z)
Number of subjects: 249
Study 24569914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 249
Study 23122972 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine dosing strategies (80% of usual dose, call physician for dose, refer to dosing table)
Number of subjects: 401
Study 23122972 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus bolus group (dosing table strategy)
Number of subjects: 401
Study 23122972 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine‐only group
Number of subjects: 401
Study 23122972 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine plus bolus group
Number of subjects: 401
Study 19543129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 753
Study 19543129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg
Number of subjects: 753
Study 19543129 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 753
Study 19543129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 753
Study 19543129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene
Number of subjects: 753
Study 17110457 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX-CBL
Number of subjects: 95
Study 17110457 — intervention group
Group type: COMPARATOR
Intervention: ATG
Number of subjects: 95
Study 16091242 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic immunization
Number of subjects: 0
Study 16091242 — intervention group
Group type: COMPARATOR
Intervention: Antiviral therapy
Number of subjects: 0
Study 12110028 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polysulfone (PS; F 60S)
Number of subjects: 74
Study 12110028 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-flux polysulfone (PS; F 500S)
Number of subjects: 74
Study 12110028 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-flux cellulosic tri-acetate (CTA)
Number of subjects: 74
Study 12110028 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-flux cellulosic tri-acetate with filtered dialysate (CTA(f))
Number of subjects: 74
Study 12110028 — intervention group
Group type: COMPARATOR
Intervention: Clinical events
Number of subjects: 74
Study 10434832 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg i.v.
Number of subjects: 80
Study 10434832 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline i.v. (placebo)
Number of subjects: 80
Study 7568532 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer case management services
Number of subjects: 91
Study 2148767 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat position for 15 minutes followed by head elevated 30 degrees for 15 minutes
Number of subjects: 4
Study 2148767 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat position for 15 minutes followed by head elevated 30 degrees with knee gatch elevated for 15 minutes
Number of subjects: 4
Study 2148767 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat position for 15 minutes followed by reverse Trendelenberg for 15 minutes
Number of subjects: 4
Study 7032305 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating gratings (15 min per week for 10 weeks)
Number of subjects: 42
Study 7032305 — intervention group
Group type: COMPARATOR
Intervention: Blank rotating disk (same duration as treatment group)
Number of subjects: 42
Study 7032305 — intervention group
Group type: COMPARATOR
Intervention: Weekly acuity evaluation without treatment (second control group)
Number of subjects: 42
Study 30665198 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT) directed at the right-side ankle and foot
Number of subjects: 84
Study 30665198 — intervention group
Group type: COMPARATOR
Intervention: No treatment (CONTROL group)
Number of subjects: 84
Study 26249232 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-2952 (3, 10, 30, 100, 200, or 400 mg)
Number of subjects: 84
Study 26249232 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-2952 (30, 60, or 100 mg/d)
Number of subjects: 84
Study 26249232 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-2952 (10 mg and 200 mg) under fasted and fed conditions
Number of subjects: 84
Study 26249232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 23526594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice pack
Number of subjects: 41
Study 23526594 — intervention group
Group type: COMPARATOR
Intervention: Cold-water immersion
Number of subjects: 41
Study 23526594 — intervention group
Group type: COMPARATOR
Intervention: Both modalities
Number of subjects: 41
Study 22134226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold vibration device placed 5 to 10 cm proximally during venipuncture
Number of subjects: 81
Study 22134226 — intervention group
Group type: COMPARATOR
Intervention: Standard care (primarily vapocoolant spray)
Number of subjects: 81
Study 22134226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold vibration device
Number of subjects: 81
Study 19138437 — intervention group
Group type: EXPERIMENTAL
Intervention: High fish oil (HFO) meal (2.2 g fish oil)
Number of subjects: 11
Study 19138437 — intervention group
Group type: COMPARATOR
Intervention: Reference (REF) meal (0.3 g fish oil)
Number of subjects: 11
Study 17350451 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy (including early routine catheterisation and revascularisation)
Number of subjects: 1200
Study 17350451 — intervention group
Group type: COMPARATOR
Intervention: Selective invasive strategy (catheterisation if refractory angina or recurrent ischaemia)
Number of subjects: 1200
Study 17350451 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1200
Study 17350451 — intervention group
Group type: COMPARATOR
Intervention: Selective invasive strategy
Number of subjects: 1200
Study 15539706 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa (15 mg on days 1, 3, and 5 after percutaneous pericardiocentesis)
Number of subjects: 33
Study 11394556 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise program (6 months, twice per week for 60 min)
Number of subjects: 94
Study 11394556 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 94
Study 9480997 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone three times daily
Number of subjects: 102
Study 9480997 — intervention group
Group type: COMPARATOR
Intervention: theophylline twice daily
Number of subjects: 102
Study 9480997 — intervention group
Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 102
Study 7818840 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (angiotensin-converting enzyme inhibitor)
Number of subjects: 10800
Study 7818840 — intervention group
Group type: COMPARATOR
Intervention: Conventional antihypertensive therapy (diuretics or beta-blockers)
Number of subjects: 10800
Study 3339551 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M style 34R plano-convex (reverse) optic posterior chamber lens
Number of subjects: 0
Study 3339551 — intervention group
Group type: COMPARATOR
Intervention: 3M style 34S convex‐plano optic posterior chamber lens
Number of subjects: 0
Study 30980399 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (lower dose)
Number of subjects: 0
Study 30980399 — intervention group
Group type: EXPERIMENTAL
Intervention: Autophagy inhibition (genetically or pharmacologically) combined with Sorafenib
Number of subjects: 0